ALIGOS THERAPEUTICS, INC.

(ALGS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aligos Therapeutics, Merck Expand Collaboration in Nonalcoholic Steatohepatitis

01/11/2022 | 10:17am EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALIGOS THERAPEUTICS, INC. -6.84% 1.09 Delayed Quote.-90.82%
MERCK & CO., INC. 2.11% 92.32 Delayed Quote.20.46%
ON SEMICONDUCTOR CORPORATION -1.83% 55.15 Delayed Quote.-18.80%
All news about ALIGOS THERAPEUTICS, INC.
05/05SVB Leerink Cuts Aligos Therapeutics to Market Perform From Outperform, Price Target to..
MT
05/04Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q1 Loss $-0.84, vs. Street Est of $-0.7..
MT
05/04ALIGOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/04Aligos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/04Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial R..
GL
05/03Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM..
GL
05/03Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM..
AQ
05/03Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM..
CI
04/27Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
AQ
04/27Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
GL
More news
Analyst Recommendations on ALIGOS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 2,58 M - -
Net income 2022 -118 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,41x
Yield 2022 -
Capitalization 46,5 M 46,5 M -
Capi. / Sales 2022 18,0x
Capi. / Sales 2023 -
Nbr of Employees 95
Free-Float 77,2%
Chart ALIGOS THERAPEUTICS, INC.
Duration : Period :
Aligos Therapeutics, Inc. Technical Analysis Chart | ALGS | US01626L1052 | MarketScreener
Technical analysis trends ALIGOS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 1,09 $
Average target price 4,70 $
Spread / Average Target 331%
EPS Revisions
Managers and Directors
Lawrence M. Blatt Chairman & Chief Executive Officer
Leonid N. Beigelman President & Director
Lesley Ann Calhoun Chief Financial Officer & Executive Vice President
Julian A. Symons Chief Scientific Officer & Executive VP
John Fry Executive Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ALIGOS THERAPEUTICS, INC.-90.82%47
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966
ICON PUBLIC LIMITED COMPANY-31.87%17 153